Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06353126
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-03-28
Brief Title:
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
Sponsor:
RenJi Hospital
Organization:
RenJi Hospital
Study Overview
Official Title:
A Prospective Single Arm Exploratory Study of Using Drug-eluting Beads Transarterial Chemoembolization Prior to Liver Transplantation in the Treatment of Hepatocellular Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of the study is to explore whether the usage of DEB-TACE Drug-Eluting Bead Transarterial Chemoembolization prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma HCC It is a single-center exploratory study The patients scheduled for living donor liver transplantation receive DEB-TACE 2 weeks prior to the surgery
The primary outcome Recurrence-free survival RFS The secondary outcome1 Overall survival OS2 Pathological response rate Pathological Response 3 Proportion of patients completing living donor liver transplantation 4 Adverse events related to DEB-TACE
The primary outcome Recurrence-free survival RFS The secondary outcome1 Overall survival OS2 Pathological response rate Pathological Response 3 Proportion of patients completing living donor liver transplantation 4 Adverse events related to DEB-TACE
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None